Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E, Negretti E, Giannotti B, Brogelli L, Brunetti I, Sertoli MR, Bernengo MG, Sofra MC, Maifredi G, Zumiani G, et al. Bajetta E, et al. Among authors: sertoli mr. Am J Clin Oncol. 1990 Oct;13(5):405-9. doi: 10.1097/00000421-199010000-00008. Am J Clin Oncol. 1990. PMID: 2220660 Clinical Trial.
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N. Sertoli MR, et al. Melanoma Res. 1999 Oct;9(5):503-9. doi: 10.1097/00008390-199910000-00010. Melanoma Res. 1999. PMID: 10596917 Clinical Trial.
A feasibility study using polychemotherapy (cisplatin + vindesine + dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma.
Bajetta E, Del Vecchio M, Vitali M, Martinetti A, Ferrari L, Queirolo P, Sertoli MR, Cainelli T, Cellerino R, Cascinelli N. Bajetta E, et al. Among authors: sertoli mr. Tumori. 2001 Jul-Aug;87(4):219-22. doi: 10.1177/030089160108700402. Tumori. 2001. PMID: 11693798 Clinical Trial.
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N. Bajetta E, et al. Among authors: sertoli mr. Ann Oncol. 2006 Apr;17(4):571-7. doi: 10.1093/annonc/mdl007. Epub 2006 Feb 9. Ann Oncol. 2006. PMID: 16469753 Free article. Clinical Trial.
Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A. Del Vecchio M, et al. Among authors: sertoli mr. Clin Cancer Res. 2010 Dec 1;16(23):5862-72. doi: 10.1158/1078-0432.CCR-10-2363. Epub 2010 Oct 28. Clin Cancer Res. 2010. PMID: 21030496 Clinical Trial.
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchianò A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Belli F, et al. Among authors: sertoli mr. J Clin Oncol. 2002 Oct 15;20(20):4169-80. doi: 10.1200/JCO.2002.09.134. J Clin Oncol. 2002. PMID: 12377960 Clinical Trial.
119 results